NCT01498120View on ClinicalTrials.gov

Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Restless Legs Syndrome
Interventions
DRUG

Rotigotine

"Optimal dose after titration period~0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2)~1 patch /day"

Trial Locations (5)

Unknown

012, Los Angeles

009, Orange

014, Spring Hill

013, Indianapolis

001, Destrehan

All Listed Sponsors
lead

UCB BIOSCIENCES, Inc.

INDUSTRY

NCT01498120 - Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome | Biotech Hunter | Biotech Hunter